The estimated Net Worth of Patrick J Md Phd Scannon is at least $298 Тысяча dollars as of 12 June 2023. Patrick Scannon owns over 1,000 units of Cassava Sciences Inc stock worth over $27,330 and over the last 21 years he sold SAVA stock worth over $237,365. In addition, he makes $33,372 as Independent Director at Cassava Sciences Inc.
Sign up
Patrick Scannon SAVA stock SEC Form 4 insiders trading
Patrick has made over 29 trades of the Cassava Sciences Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of SAVA stock worth $950 on 12 June 2023.
The largest trade he's ever made was exercising 105,000 units of Cassava Sciences Inc stock on 23 December 2003 worth over $268,800. On average, Patrick trades about 7,409 units every 113 days since 2003. As of 12 June 2023 he still owns at least 1,000 units of Cassava Sciences Inc stock.
You can see the complete history of Patrick Scannon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patrick Scannon biography
Dr. Patrick J. Scannon M.D., Ph.D. serves as Independent Director of the Company. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon retired from XOMA and resigned from XOMA’s board of directors in 2016. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.
What is the salary of Patrick Scannon?
As the Independent Director of Cassava Sciences Inc, the total compensation of Patrick Scannon at Cassava Sciences Inc is $33,372. There are 8 executives at Cassava Sciences Inc getting paid more, with Remi Barbier having the highest compensation of $1,073,230.
How old is Patrick Scannon?
Patrick Scannon is 72, he's been the Independent Director of Cassava Sciences Inc since 2007. There are 4 older and 5 younger executives at Cassava Sciences Inc. The oldest executive at Cassava Sciences Inc is Sanford Robertson, 88, who is the Independent Director.
What's Patrick Scannon's mailing address?
Patrick's mailing address filed with the SEC is 6801 N CAPITAL OF TEXAS HWY, BLDG 1, SUITE 300, AUSTIN, TX, 78731.
Insiders trading at Cassava Sciences Inc
Over the last 6 years, insiders at Cassava Sciences Inc have traded over $0 worth of Cassava Sciences Inc stock and bought 1,178,376 units worth $9,853,781 . The most active insiders traders include Sanford Robertson, Richard Barry и Patrick J Md Phd Scannon. On average, Cassava Sciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $1,235,207. The most recent stock trade was executed by Sanford Robertson on 26 April 2024, trading 69,000 units of SAVA stock currently worth $1,518,000.
What does Cassava Sciences Inc do?
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
What does Cassava Sciences Inc's logo look like?
Complete history of Patrick Scannon stock trades at XOMA Royalty и Cassava Sciences Inc
Cassava Sciences Inc executives and stock owners
Cassava Sciences Inc executives and other stock owners filed with the SEC include:
-
Remi Barbier,
Chairman of the Board, President, Chief Executive Officer -
Remi Barbier,
Founder, Chairman, Pres & CEO -
Nadav Friedmann,
Chief Medical and Operating Officer, Director -
Dr. Nadav Friedmann,
Chief Medical Officer & Director -
Eric J. Schoen,
Chief Financial Officer -
Eric Schoen,
Chief Financial Officer -
Sanford Robertson,
Independent Director -
Robert Gussin,
Independent Director -
Patrick Scannon,
Independent Director -
Michael O' Donnell,
Independent Director -
Dr. James W. Kupiec M.D.,
Chief Clinical Devel. Officer -
Dr. Lindsay H. Burns Ph.D.,
Sr. VP of Neuroscience -
Dr. Michael Marsman,
Sr. VP of Regulatory Affairs -
Michael Zamloot,
Sr. VP of Technical Operations -
Dr. George Thornton,
Sr. VP of Technology -
Saira Ramasastry,
Director -
Pierre Gravier,
Director -
Claude Nicaise,
Director -
Robert Christopher Cook,
SVP & General Counsel -
Richard Barry,
Director -
James William Kupiec,
Chief Medical Officer -
Robert Eugene Jr Anderson,
Director